Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA) is a late clinical-stage biopharmaceutical company based in the Seattle, Washington area, dedicated to developing small molecule therapeutics aimed at restoring neuronal health and slowing neurodegeneration. Athira's innovative pipeline includes several promising compounds, particularly targeting the neurotrophic hepatocyte growth factor (HGF) system, which plays a crucial role in nervous system maintenance and repair.
The company’s lead candidate, Fosgonimeton (ATH-1017), is a subcutaneously administered small molecule designed to positively modulate the HGF/MET system. It is currently being evaluated in the Phase 2/3 LIFT-AD clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, with topline data expected in the second half of 2024. Fosgonimeton has shown potential in enhancing neuroprotective, neurotrophic, and anti-inflammatory pathways, which are critical in combating neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
In addition to Fosgonimeton, Athira’s pipeline includes ATH-1105 and ATH-1020, both designed to be orally available treatments enhancing the HGF/MET system. ATH-1105 is particularly promising in preclinical models of amyotrophic lateral sclerosis (ALS), demonstrating significant neuroprotective effects, enhanced survival, and improved motor and nerve functions. The company plans to initiate first-in-human studies for ATH-1105 in the first half of 2024.
Athira's research is bolstered by funding from notable organizations such as the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, and Dolby Family Ventures. This support underscores the company’s strong financial position and its capacity to advance its therapeutic candidates through key development milestones.
Recent updates highlight the therapeutic potential of Athira’s small molecules. For instance, fosgonimeton has demonstrated promising results in preclinical models of Alzheimer’s and Parkinson’s diseases, showing neuroprotective effects and improvement in cognitive and motor functions. Additionally, ATH-1105's preclinical studies have shown consistent beneficial effects in ALS models, reinforcing Athira’s approach and commitment to developing novel therapies for neurodegenerative diseases.
Athira is also active in the scientific community, regularly presenting its findings at major conferences and publishing in peer-reviewed journals. The company’s efforts are focused on leveraging its patented technologies to develop cost-effective treatments that address the root causes of neurodegenerative diseases, setting it apart from competitors that primarily target disease symptoms.
For more information about Athira Pharma, Inc., visit www.athira.com and follow the company on Facebook, LinkedIn, X (formerly known as Twitter), and Instagram.
Athira Pharma (NASDAQ: ATHA) presented new biomarker data from the completed ACT-AD Phase 2 study of fosgonimeton, showing significant reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) that correlate with improved clinical outcomes in mild-to-moderate Alzheimer’s patients. Fosgonimeton treatment also demonstrated directional improvements in Alzheimer’s protein pathologies compared to placebo. The company continues to progress in its Phase 2/3 LIFT-AD study, aiming for topline data release in early 2024.
Athira Pharma announced positive preclinical data for its small molecule, ATH-1105, showing neuroprotective effects and improved motor and nerve function in a TDP-43 mouse model of ALS. The findings will be presented at the upcoming Motor Neurone Disease Association’s 33rd International Symposium on ALS/MND, scheduled for December 6-9, 2022. This research highlights ATH-1105's therapeutic potential in neurodegenerative conditions, aligning with Athira's mission to restore neuronal health.
Athira Pharma, Inc. (NASDAQ: ATHA) announced promising preclinical results at Neuroscience 2022 regarding fosgonimeton, a small molecule aimed at treating Parkinson’s disease and diabetic neuropathy. The findings indicate that fosgonimeton promotes neuroprotection and enhances motor performance in Parkinson’s models. Additionally, HGF/MET modulators ATH-1018 and ATH-1020 showed significant pain reduction in diabetic neuropathy, sustaining effects even after washout periods. These developments highlight Athira's commitment to advancing treatments for neurodegeneration and pain management.
Athira Pharma (NASDAQ: ATHA) reported interim results from its LIFT-AD study, indicating potential efficacy of fosgonimeton in treating mild-to-moderate Alzheimer's disease. The independent analysis showed clinically meaningful activity without acetylcholinesterase therapy, suggesting the study can meet its primary endpoint with fewer than 150 additional patients. Financially, Athira holds $260 million in cash as of September 30, 2022, although it reported a net loss of $20.2 million for the quarter. The company anticipates completing enrollment by mid-2023 and plans to release topline data in early 2024.
Athira Pharma, Inc. (NASDAQ: ATHA), a biopharmaceutical company focused on neurodegenerative diseases, will participate in the Stifel 2022 Healthcare Conference on November 15-16, 2022, in New York City. Management will host a fireside chat on November 16 at 4:45 p.m. EST. Interested parties can access a live webcast through the Investors section of Athira's website, with an archived replay available for 30 days post-event. Athira aims to develop small molecules for conditions like Alzheimer's and Parkinson's disease, targeting the HGF/MET neurotrophic system.
Athira Pharma announced the presentation of preclinical data on the therapeutic potential of enhancing the HGF/MET neurotrophic system for treating Parkinson’s disease and diabetic neuropathy at Neuroscience 2022. Presentations include 'Small Molecule Hepatocyte Growth Factor (HGF)/MET Positive Modulators Effectively Reduce Pain-Related Behaviors in a Rat Model of Diabetic Neuropathy' and 'Fosgonimeton Protects Against Neuronal Damage and Motor Deficits in Preclinical Models of Parkinson’s Disease'. Both presentations are scheduled for Nov. 14 and Nov. 15, 2022, respectively.
Athira Pharma announced positive interim results for its LIFT-AD study on fosgonimeton (ATH-1017) in Alzheimer’s patients. An independent committee recommended continuing the trial after finding it well powered with fewer than 300 patients enrolled and a preliminary positive effect size. The company aims to complete enrollment by mid-2023 and report topline results in early 2024. Previous Phase 2 results showed a favorable safety profile and cognitive benefits. The firm is optimistic about fosgonimeton's potential in treating Alzheimer's and plans further development.
Athira Pharma (NASDAQ: ATHA) announced updates on its LIFT-AD clinical trial of fosgonimeton, focusing on its use as monotherapy for mild-to-moderate Alzheimer's disease. Following positive results from the ACT-AD trial, the company will amend LIFT-AD to compare fosgonimeton alone against placebo, without background acetylcholinesterase inhibitors. An independent interim analysis will ensure the trial's sample size is sufficient for the primary endpoint, the Global Statistical Test. Over 90% of ACT-AD participants have opted for the ongoing open-label extension study.
Athira Pharma reported Q2 2022 financial results, revealing cash reserves of $282.2 million and a net loss of $24.3 million, or $0.65 per share. The ACT-AD Phase 2 trial of fosgonimeton showed no statistical significance for its primary endpoint, yet indicated potential cognitive improvement in post hoc analysis. Clinical updates include ongoing recruitment for the LIFT-AD Phase 3 study and promising preclinical data on new HGF/MET modulators. The company highlighted a strong balance sheet, supporting its ongoing clinical development pipeline.
Athira Pharma (ATHA) presented results from its ACT-AD trial for fosgonimeton, a treatment for mild-to-moderate Alzheimer's disease, at the AAIC 2022. While the primary endpoint was not statistically significant, secondary analyses showed numerical improvements in daily living activities and cognitive measures. Notably, a significant reduction in neurofilament light chain (NfL), a biomarker of neurodegeneration, was observed in a subgroup receiving fosgonimeton monotherapy. The positive tolerability profile and ongoing LIFT-AD study offer further exploration into its therapeutic potential.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
What is Athira Pharma, Inc.?
What are Athira's lead compounds?
What is the focus of Athira's research?
When are the next significant milestones for Athira?
Who funds Athira's research?
What differentiates Athira's approach from other companies?
What is Fosgonimeton?
What recent achievements has Athira reported?
How does Athira contribute to the scientific community?
Where can I find more information about Athira Pharma?
